Frequency of Neonatal Hyperglycemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-11-01

Study Completion Date

2025-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Detection of prevalence of neonatal hyperglycemia and assessment of risk factors, clinical characteristics and possible complications of neonatal hyperglycemia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of a Hypoglycemia Protocol With Glucose Gel on Neonatal Intensive Care Unit (NICU) Admission

NCT04085978

Hypoglycemia Neonatal Hypoglycemia

TERMINATED

Incidence and Course of Stress Hyperglycemia in Critically Ill Children Admitted to PICU of Assiut University Children Hospital

NCT04591561

Stress Hyperglycemia

UNKNOWN

Hypoglycemic and Hyperglycemic Disorders

NCT03448965

Hypoglycemia in Newborn Infants Hyperglycemia

UNKNOWN

To Examine if the Mother's Glucose Levels and Glucose Levels in the Blood Can Predict Cord Hypoglycemia in Newborns at Risk.

NCT02838875

Neonatal Hypoglycemia

UNKNOWN PHASE3

Impact of Blood Glucose Levels on in ICU Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

NCT06453967

Heart Failure

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hyperglycemia has become an important risk factor for mortality and morbidity in the neonatal period, especially with increased survival rates of very low birth weight neonates.

Neonatal hyperglycemia is usually defined as serum glucose greater than 150 mg/dl (8.3 mmol/L) or whole blood glucose greater than 125 mg/dl (6.9 mmol/L) irrespective of gestational or postmenstrual age. Usually, the safe target for a neonate's serum glucose level is 70 to 150 mg/dl. The cut off for safe target is based on the renal glucose threshold of preterm neonates.

Hyperglycemia is more common in preterm infants than term infants as it occurs in one-third of preterm and small gestational age (SGA) infants and is generally noted during the first week of life. Usually, the acute hyperglycemia resolves over two to three days in most neonates but can last up to ten days. Hyperglycemia is less common than hypoglycemia among neonates but is associated with increased mortality and morbidity among neonates. Neonatal hyperglycemia is inversely related to birth weight and gestational age.

Glucose is an essential source of energy for the fetus and neonate. The brain growth of the fetus exclusively depends upon glucose. In the early postnatal period, glucose homeostasis occurs via glycogenolysis and gluconeogenesis. The critical regulatory mechanisms of glucose homeostasis are sluggish in the initial days, particularly among preterm neonates. The mechanisms of neonatal hyperglycemia are multifactorial. The risk of hyperglycemia increases with the severity of the accompanying illness. The most common cause is high exogenous glucose infusion rates (GIR) in preterm infants who are already at risk for hyperglycemia due to the following reasons,

* decreased ability to suppress endogenous glucose production,
* decreased insulin response to glucose, and
* limited glycogen and fat stores. Hyperglycemia in the neonatal period develops as a result of other multiple risk factors including.

Intrauterine growth restriction, increased stress hormones like epinephrine and norepinephrine inhibit both insulin secretion and action, causes related to enteral feeding as delay in the initiation of enteral feeding causes decreased incretin secretion, which in turn causes hyperglycemia. and the hyperosmolar formula may lead to transient glucose intolerance in the baby. , causes related to Total parenteral nutrition (TPN) as delay in supplementing parenteral amino acids in TPN delays the release of insulin-like growth factor-1, which delays the development of beta cells in the pancreas and develops hyperglycemia and a high intravenous lipid infusion rate causes an increase in free fatty acids (FFA), which decrease glucose oxidation competitively by providing additional carbon substrates for oxidative metabolism. FFA and glycerol promote gluconeogenesis, sepsis, iatrogenic as error in the glucose infusion rate (GIR) calculation in the intravenous (IV) fluid, transient neonatal diabetes mellitus and permanent diabetes mellitus, drugs as maternal medications as maternal Diazoxide may cause hyperglycemia, hypotension, and tachycardia in neonates, antenatal steroids, neonatal medications as dopamine, dobutamine, epinephrine infusions, caffeine, theophylline, Phenytoin and Corticosteroids.

Neonatal diabetes can be of three different types.

1. The transient form accounts for more than 50%. It is usually associated with mutations of sulfonylurea receptors. Transient neonatal diabetes manifests soon after birth and remits spontaneously in 6 months.
2. Permanent neonatal diabetes needs lifelong management. Mutations in the genes encoding the subunit of the ATP-sensitive potassium channel is the most common cause.
3. Syndromic Neonatal diabetes is usually associated with syndromes like Wolfram syndrome, IPEX syndrome (immune dysregulation polyendocrinopathy X linked syndrome).

The severity of impact increases with prolonged hyperglycemia as intracranial hemorrhage by causing hyperosmolarity with osmotic shifts, dehydration due to osmotic diuresis, electrolyte imbalance occurs due to osmotic diuresis. Glycosuria also increases sodium excretion, NEC , retinopathy of prematurity , bronchopulmonary disease, Impaired immunity and increased risk of sepsis, poor wound healing and adverse neurodevelopmental outcome.

In general, Neonatal hyperglycemia is associated with a clinical condition rather than a specific disorder of glucose metabolism. Neonatal hyperglycemia can be a sign of an underlying illness.

In preterm and very-low-birth-weight (VLBW) infants, i.e., infants with birth weight less than 1500 grams, a consistent blood glucose level of more than 200 mg/dL is a cause for concern. A blood glucose level measured as \>200 mg/dL with a 4-hour interval and glucosuria of +2 or more necessitates treatment. Currently, hyperglycemia treatment in the absence of an increase in osmolarity and osmotic diuresis is not supported.

1. The first step in evaluating neonatal hyperglycemia is to assess the GIR. GIR = IV infusion rate (mL/kg/day) x Dextrose concentration (%) / 144 The GIR is lowered by reducing IV dextrose concentration or the infusion rate. GIR can be decreased by 1 to 2 mg/kg/min every 2 hours, with frequent glucose monitoring until the GIR reaches 4 mg/kg/min.
2. In case of persistent hyperglycemia, underlying causes such as sepsis, stress, medications need to be explored and treated accordingly.
3. Role of Insulin

* Hyperglycemia persisting at low GIR (4 mg/kg/min) may indicate relative insulin deficiency or insulin resistance.
* The role of insulin therapy in treating hyperglycemia in neonates is controversial. Consider insulin if blood glucose level is more than 250 mg/dl, and if urine glucose is more than 2+ in two separate samples obtained four hours apart.
* It is crucial to monitor serum glucose levels every 1 hour when the infant is on insulin. Measure the blood glucose level half an hour after each change in insulin infusion
4. Any electrolyte imbalance due to osmotic diuresis should be corrected. Sodium and potassium imbalance is very common.

Hyperglycemia needs to be prevented in all neonates, particularly among preterm infants, due to associated complications such as the increased risk for infection, impaired immunity, poor wound healing, increased morbidity, and mortality. The following preventive measures help in the practice to prevent hyperglycemia.

1. Early initiation of enteral feedings
2. Early supplementation of amino acids in TPN, leading to an increase in insulin secretion that prevents hyperglycemia.
3. Targeting optimal and physiologic GIR in TPN as per the glucose monitoring
4. Limiting IV lipid infusions during hyperglycemia
5. A more direct and immediate approach is to decrease the catecholamine infusions as tolerated.
6. Discontinuing catecholamine infusions and glucocorticoid treatments as soon as the infant;s condition has improved.